Vitrolife signs collaboration agreement with Cellartis

Vitrolife has entered into a new 3-year collaboration agreement with Cellartis AB regarding the development of new products for the culture, handling and differentiation of stem cells. The agreement extends the previous collaboration between the companies.

“The stem cell field is experiencing strong growth, not least since President Obama lifted the ban on research into certain stem cell lines,” says Tony Winslöf, Head of Business Development at Vitrolife. The collaboration with Cellartis comes at the right time to develop the stem cell products of tomorrow, meeting the scientific, regulatory and commercial demands of the future. “Cellartis is a world-leading company with regard to competence above all in the field of pluripotent stem cells, and as such is a valuable resource in developing the right products for a rapidly growing market,” says Magnus Nilsson, Vitrolife’s CEO, who also points out that "stem cell culture is difficult and both Vitrolife and Cellartis have long experience of optimizing culture environments for sensitive cells." The financial scope of the agreement will not be made public. Gothenburg October 8, 2009 Magnus Nilsson CEO Queries should be addressed to: Magnus Nilsson, CEO, phone +46 31 721 80 61. Eva Nilsagård, CFO, phone +46 31 721 80 13.

About Us

Vitrolife is an international medical device Group. The Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. Vitrolife has approximately 330 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid Cap.

Subscribe

Documents & Links